CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
October 2021—Cepheid received FDA emergency use authorization for its Xpert Xpress CoV-2/Flu/RSV Plus, a rapid molecular diagnostic test for qualitative detection of the viruses causing COVID-19, flu A, flu B, and respiratory syncytial virus infections from a single patient sample. The Plus version of the test provides three gene targets for SARS-CoV-2 detection—N2, E, and RdRP. The test is designed for use on any GeneXpert system and results are delivered in about 36 minutes.
Pages: 1 2